-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target

Benzinga·03/13/2026 11:37:29
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $60 price target.